Novo Nordisk: starts to collaborate with Kallyope
(CercleFinance.com) - The world's largest diabetes drugmaker, Denmark's Novo Nordisk, has entered into a research collaboration with US biotech firm Kallyope to discover novel therapeutics to treat obesity and diabetes.
Under the terms of the agreement, Novo Nordisk will have an option to license exclusive worldwide rights to develop and commercialize up to six peptide products discovered in the partnership.
In exchange, Kallyope will receive an upfront payment and research support for activities conducted in the collaboration.
The firm will also receive a license fee if Novo Nordisk chooses to exercise an option to a therapeutic discovered and validated in the joint research plan.
In addition, Kallyope will receive royalties on worldwide product sales of licensed products.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
Under the terms of the agreement, Novo Nordisk will have an option to license exclusive worldwide rights to develop and commercialize up to six peptide products discovered in the partnership.
In exchange, Kallyope will receive an upfront payment and research support for activities conducted in the collaboration.
The firm will also receive a license fee if Novo Nordisk chooses to exercise an option to a therapeutic discovered and validated in the joint research plan.
In addition, Kallyope will receive royalties on worldwide product sales of licensed products.
Copyright (c) 2018 CercleFinance.com. All rights reserved.